FDA Output, September 2024
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in September 2024. Updated September 18.
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Diagnostic Emergency Use Authorizations in September 2024. Updated September 18.
Peter Fitzgerald launches an educational program aimed at expanding opportunities for Israeli and Palestinian youth.
China NMPA publishes a draft medical device management law. Excerpted from Pathways’ Picks September 4: China Reform, De Novo Details, and Global Picks.